This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
n8	http://dx.doi.org/10.1136/
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q45358499

rdf:type

wikibase:Item

schema:description

научни чланак 2009 nî lūn-bûn научни чланак научна статия artículu científicu scientific article published on 21 April 2009 articol științific teaduslik artikkel bilimsel makale 2009年学术文章 სამეცნიერო სტატია wissenschaftlicher Artikel artigo científico 2009年學術文章 article scientific 2009年学术文章 επιστημονικό άρθρο 2009年の論文 2009年学术文章 vitenskapelig artikkel مقالة علمية نشرت في 21 أبريل 2009 naučni članak article científic 2009年學術文章 videnskabelig artikel artikel ilmiah vědecký článek scientific article published on 21 April 2009 vetenskaplig artikel artikulong pang-agham 2009年学术文章 tudományos cikk 2009年學術文章 tieteellinen artikkeli artigo científico vitskapeleg artikkel articolo scientifico наукова стаття, опублікована у квітні 2009 scienca artikolo article scientifique ২১ এপ্রিল ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научная статья vedecký článok 2009年學術文章 scientific article published on 21 April 2009 bài báo khoa học artikull shkencor 2009년 논문 2009年学术文章 บทความทางวิทยาศาสตร์ מאמר מדעי 2009年學術文章 wetenschappelijk artikel мақолаи илмӣ 2009年学术文章 artículo científico publicado en 2009 artigo científico artykuł naukowy

p:P577

wds:Q45358499-858B7FA1-5D1C-4867-AB55-D068FD1B7A66

wdt:P577

2009-04-21T00:00:00Z

p:P407

wds:Q45358499-6606C0B1-8D33-4C12-A255-02CAA38A21C9

wdt:P407

wd:Q1860

p:P2093

wds:Q45358499-187F60FA-DAB0-46C1-88CB-80FD8C1FA321 wds:Q45358499-AE27A97D-80D6-436A-947F-ED79916C0AC1

wdt:P2093

G Haugeberg M Quinn

rdfs:label

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

skos:prefLabel

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

schema:name

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

p:P50

wds:Q45358499-BDA7356B-7587-42E2-B42F-AA583DF3C17A wds:Q45358499-F03D92D0-7A2A-417F-89D7-3816E4852A9C

wdt:P50

wd:Q19859634 wd:Q37829390

p:P1476

wds:Q45358499-D07BE908-19C1-447F-A0B9-8A11EC73C23E

wdt:P1476

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

p:P304

wds:Q45358499-5EFA4822-74E1-44D0-A49E-260CDB628469

wdt:P304

1898-1901

p:P31

wds:Q45358499-B992BD88-7612-46EF-9CF1-58B9BAE51AC4

wdt:P31

wd:Q13442814

p:P921

wds:Q45358499-2D0E7FBB-4EB2-4575-AF57-39674CDD22EF wds:Q45358499-31AC357B-E1BE-496B-A1F3-66CC93A53A82 wds:Q45358499-41A7E22E-5BFD-4085-8DE5-611D13A6AE83 wds:Q45358499-28D36FCA-EAC5-4438-AB8C-624239BC8E87

wdt:P921

wd:Q422232 wd:Q187255 wd:Q181600 wd:Q269829

p:P698

wds:Q45358499-BC817FFD-4304-4DE4-ABEB-C467E097438E

wdtn:P698

n12:19386610

wdt:P698

19386610

p:P1433

wds:Q45358499-76F69761-F2C6-40AF-8578-5BCCAEC403F3

wdt:P1433

wd:Q4767876

p:P433

wds:Q45358499-F533ECD3-83F9-4982-9DA5-9B80B24EFEF5

p:P478

wds:Q45358499-C25B374F-E9F1-438A-9943-84721252CCE6

wdt:P433

12

wdt:P478

68

p:P356

wds:Q45358499-694541C3-E6D3-45EC-AF0B-836A6AA21FE9

wdtn:P356

n8:ARD.2008.106484

wdt:P356

10.1136/ARD.2008.106484

p:P8608

wds:Q45358499-4BCCB857-C3CC-49AC-99E5-03D56FE81DFC

wdt:P8608

release_wwetr2uibbfwhct6y3jcrwj7am

p:P6179

wds:Q45358499-6D8216BA-ABD7-4EE7-A076-E30F64FB9B7E

wdt:P6179

1007071632